Signs of striatal dopamine transporter density increase in association with improvement of tardive dyskinesia in a patient with schizophrenia, as demonstrated by a DAT scan

被引：7

作者：

Rizos, E. N. ^{[1
]}

Chatziioannou, S. ^{[2
]}

Douzenis, A. ^{[1
]}

Siafakas, N. ^{[3
]}

Katsantoni, E. ^{[4
]}

Nikolaidou, P. ^{[1
]}

Papathanasiou, M. ^{[2
]}

Lykouras, L. ^{[1
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Sch Med, Dept Psychiat 2, ATTIKON Gen Hosp, Athens 12462, Greece

[2] Univ Athens, Sch Med, ATTIKON Hosp, Dept Radiol B, GR-10679 Athens, Greece

[3] Natl & Kapodistrian Univ Athens, Sch Med, Microbiol Labs, ATTIKON Gen Hosp, Athens 12462, Greece

[4] Acad Athens, Div Hematol Oncol, Biomed Res Fdn, Athens, Greece

来源：

EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2010年 / 20卷 / 02期

关键词：

Tardive dyskinesia; Olanzapine; Quetiapine; DAT scan; Ser9Gly DRD3-5HT2C; polymorphisms; ATYPICAL ANTIPSYCHOTICS; RECEPTOR GENE; QUETIAPINE; OLANZAPINE; BINDING; TRIAL; D-2;

D O I：

10.1016/j.euroneuro.2009.08.002

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The imaging of the dopamine transporter could demonstrate the implication of dopaminergic pathway in the appearance of tardive dyskinesia. We report a case with psychotic and tardive dyskinesia symptoms. A DAT scan showed decreased dopamine transporter uptake in the area of brain's basal gaglia. A trial with quetiapine improved both psychotic and TD symptoms while a second DAT scan showed improvement status. We conclude that increased dopamine transporter uptake seemed to associate with the improvement of TD. (C) 2009 Elsevier B.V. and ECNP. All rights reserved.

引用

页码：132 / 136

页数：5

共 24 条

[1] The Impact of Olanzapine on Tardive Dyskinetic Symptoms in a State Hospital Population [J].

Brar, Jaspreet S. ;

Parepally, Haranath ;

Chalasani, Lokaranjit ;

Gopalant, Aziz ;

Appel, Nicole ;

Chengappa, K. N. Roy .

ANNALS OF CLINICAL PSYCHIATRY, 2008, 20 (03) :139-144

[2] Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α1,-adrenergic receptors in vitro [J].

Bymaster, FP ;

Nelson, DL ;

DeLapp, NW ;

Falcone, JF ;

Eckols, K ;

Truex, LL ;

Foreman, MM ;

Lucaites, VL ;

Calligaro, DO .

SCHIZOPHRENIA RESEARCH, 1999, 37 (01) :107-122

[3] Atypical antipsychotics, tardive dyskinesia, and D2 receptors [J].

Duggal, Harpreet S. ;

Mendhekar, Dattatreya Namdeorao .

AMERICAN JOURNAL OF PSYCHIATRY, 2006, 163 (08) :1449-1450

[4]

Emsley R, 2004, J CLIN PSYCHIAT, V65, P696

[5] D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia:: a PET study [J].

Gefvert, O ;

Lundberg, T ;

Wieselgren, IM ;

Bergström, M ;

Långström, B ;

Wiesel, FA ;

Lindström, L .

EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2001, 11 (02) :105-110

[6] TARDIVE-DYSKINESIA [J].

JESTE, DV ;

CALIGIURI, MP .

SCHIZOPHRENIA BULLETIN, 1993, 19 (02) :303-315

[7] New atypical antipsychotic medications [J].

Jibson, MD ;

Tandon, R .

JOURNAL OF PSYCHIATRIC RESEARCH, 1998, 32 (3-4) :215-228

[8]

Kane JM, 2004, J CLIN PSYCHIAT, V65, P16

[9] Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?:: A new hypothesis [J].

Kapur, S ;

Seeman, P .

AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (03) :360-369

[10] Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods [J].

Kinon, BJ ;

Jeste, DV ;

Kollack-Walker, S ;

Stauffer, V ;

Liu-Seifert, H .

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2004, 28 (06) :985-996

← 1 2 3 →